Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. News
  5. Deals

Deals

Evaluate

Thumbnail
March 23, 2023

Cognito gets $73m and hopes to do better this time

Thumbnail
March 22, 2023

Roche and Lilly Eapp into Alzheimer’s testing

Article image
Vantage logo
February 22, 2023

All quiet on the deal front... or perhaps it’s just February

Article image
Vantage logo
February 15, 2023

Bavarian boosts its travel vaccine offering

Article image
Vantage logo
February 13, 2023

Mineralys takes on J&J and Astrazeneca

Article image
Vantage logo
February 10, 2023

Seven plus eight makes six for Globus

The purchase of Nuvasive for $3.1bn is the biggest ortho deal for some time – and integration will be tough.

Article image
Vantage logo
February 10, 2023

Allurion feels the Spac allure

Article image
Vantage logo
February 09, 2023

Abbott goes peripheral for $890m

Article image
Vantage logo
February 09, 2023

Does Novartis really love lentiviral?

The company is rumoured to be pursuing Avrobio, which would be a bargain even by gene therapy standards.

Article image
Vantage logo
February 06, 2023

Structure proves obesity works in lean times

Article image
Vantage logo
January 23, 2023

The world's twelfth VEGF drug will be sold by Takeda

The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up